This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Benzinga17 days agoDFTX
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
Benzinga17 days agoDFTX
Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.
Benzinga21 days agoDFTX
Jones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
Benzinga22 days agoDFTX
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.
Benzinga22 days agoDFTX
RBC Capital Maintains Outperform on Definium Therapeutics, Raises Price Target to $66
RBC Capital analyst Brian Abrahams maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $66.
Benzinga22 days agoDFTX
Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72
Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $68 to $72.
Benzinga22 days agoDFTX
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $75
Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $57 to $75.
Benzinga22 days agoDFTX